Autopsy report · NCT06461949

Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray

“Closed by sponsor, lack of enrollment.”

The sponsor’s own words in the registry.

Life of this trial

• Withdrawn before it enrolled anyone. Its dates are the sponsor's plans, not events that happened.

Vital statistics

Status

Withdrawn

Phase

Phase 3

Sponsor

National Institute on Deafness and Other Communication Disorders (NIDCD)

Sponsor type

US National Institutes of Health

Conditions

Allergic Fungal Rhinosinusitis (AFRS); Chronic Rhinosinusitis (CRS); Asthma; Nasal Polyps

Interventions

Dupilumab

Participants

0

Trials that died the same way

• Leptin in Human Energy and Neuroendocrine Homeostasis
  “Closed by sponsor. Lack of funding.” (86% match in meaning)
• Efficacy and Safety Study of CB-5945 for the Treatment of Opioid-Induced Constipation
  “Sponsor decision due to lack of enrollment.” (83% match in meaning)
• A Clinical Investigation Evaluating Peristeen® Performance
  “Lack of enrollment - Sponsor decision” (78% match in meaning)
• Doravirine and Weight Gain in Antiretroviral Naive
  “Due to No/Low enrollment” (77% match in meaning)
• The Metabolomics of Anaphylaxis
  “We are closing the study because of lack of enrollment.” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.